The chart below shows how DHR performed 10 days before and after its earnings report, based on data from the past quarters. Typically, DHR sees a -0.37% change in stock price 10 days leading up to the earnings, and a -1.54% change 10 days following the report. On the earnings day itself, the stock moves by -1.29%. This data can give you a slight idea of what to expect for the next quarter's release.
Positive
Q4 2024 Sales Performance: Sales for Q4 2024 reached $6.5 billion, reflecting a 1% core revenue growth, demonstrating resilience in the company's performance despite market challenges.
Improved Operating Profit Margin: Adjusted operating profit margin for Q4 improved by 90 basis points to 29.6%, driven by effective cost savings initiatives, highlighting operational efficiency.
Strong Free Cash Flow: Free cash flow generated in Q4 amounted to $1.5 billion, contributing to a robust free cash flow to net income conversion ratio of approximately 135% for the year, underscoring strong cash generation capabilities.
Bioprocessing Revenue Growth: The bioprocessing segment experienced high single-digit core revenue growth, with a sustained positive momentum in order growth for six consecutive quarters, indicating strong demand in this area.
Share Repurchase Strategy: Danaher deployed approximately $7 billion towards share repurchases in 2024, including 28 million shares, reflecting confidence in the company's value and commitment to returning capital to shareholders.
Negative
Core Revenue Decline: Core revenue declined 1.5% year over year, indicating a decrease in overall sales performance for the company.
Diagnostics Revenue Decline: Core revenue in the Diagnostics segment decreased by 2%, reflecting challenges in this area compared to previous periods.
Genomics Revenue Decline: Core revenue in the genomics consumables business declined in the quarter, with growth in next generation sequencing products not enough to offset losses in other areas.
Core Revenue Decline Forecast: The guidance for Q1 2025 anticipates a low single digit decline in core revenue, suggesting continued struggles in the upcoming quarter.
Operating Profit Margin Decline: The adjusted operating profit margin for 2025 is expected to decrease to approximately 26.5%, down from previous levels, indicating potential pressure on profitability.
Earnings call transcript: Danaher Q4 2024 sees revenue beat, stock rises
DHR.N
-2.25%